Gabriele De Marco

ORCID: 0000-0003-2406-161X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Spondyloarthritis Studies and Treatments
  • Psoriasis: Treatment and Pathogenesis
  • Rheumatoid Arthritis Research and Therapies
  • Autoimmune and Inflammatory Disorders Research
  • Bone and Joint Diseases
  • COVID-19 Clinical Research Studies
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19
  • Acute Lymphoblastic Leukemia research
  • Inflammasome and immune disorders
  • Musculoskeletal synovial abnormalities and treatments
  • Inflammatory Myopathies and Dermatomyositis
  • Cancer Immunotherapy and Biomarkers
  • Immunodeficiency and Autoimmune Disorders
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Systemic Sclerosis and Related Diseases
  • Dermatology and Skin Diseases
  • Dermatological and COVID-19 studies
  • Hip disorders and treatments
  • Venous Thromboembolism Diagnosis and Management
  • Lymphoma Diagnosis and Treatment
  • Advanced MRI Techniques and Applications
  • Electrolyte and hormonal disorders
  • Medical Imaging and Pathology Studies

NIHR Leeds Musculoskeletal Biomedical Research Unit
2016-2025

University of Leeds
2016-2025

Leeds Teaching Hospitals NHS Trust
2016-2024

Mid Yorkshire Hospitals NHS Trust
2023-2024

Chapel Allerton Hospital
2016-2024

Charité - Universitätsmedizin Berlin
2021

Klinikum Bielefeld
2021

National Health Service
2020

National Institute for Health Research
2020

Associazione Nazionale Medici Cardiologi Ospedalieri
2017

Infectious diseases and vaccines can occasionally cause new-onset or flare of immune-mediated (IMDs). The adjuvanticity the available SARS-CoV-2 is based on either TLR-7/8 TLR-9 agonism, which distinct from previous a common pathogenic mechanism in IMDs.We evaluated IMD flares new disease onset within 28-days vaccination at five large tertiary centres countries with early adoption, three Israel, one UK, USA. We assessed pattern expression terms autoimmune, autoinflammatory, mixed phenotype...

10.3390/vaccines9050435 article EN cc-by Vaccines 2021-04-29

<h3>Background</h3> The transition from psoriasis (PsO) to psoriatic arthritis (PsA) and the early diagnosis of PsA is considerable scientific clinical interest for prevention interception PsA. <h3>Objective</h3> To formulate EULAR points consider (PtC) development data-driven guidance consensus trials practice in field or management people with PsO at risk development. <h3>Methods</h3> A multidisciplinary task force 30 members 13 European countries was established, standardised operating...

10.1136/ard-2023-224148 article EN Annals of the Rheumatic Diseases 2023-06-09

Subjects with subclinical psoriatic arthritis (PsA), defined as the presence of arthralgia in psoriasis (PsO), are at higher risk PsA but scant real-world data exist. Our aims were to (1) estimate probability development PsA, (2) characterise symptoms and (3) determine clinical patterns diagnosis.

10.1136/rmdopen-2024-004314 article EN cc-by-nc RMD Open 2024-04-01

Objective. To identify the clinical features that can help to distinguish between psoriatic arthritis (PsA) and fibromyalgia (FM). Methods. Our cross-sectional study was carried out in 10 Italian rheumatology centers January September 2009, enrolled all consecutive patients with PsA FM who agreed participate. Standard laboratory data for were collected from patients. Records made of somatic symptoms, response nonsteroidal antiinflammatory drugs (NSAID), self-evaluated pain, general health,...

10.3899/jrheum.110893 article EN The Journal of Rheumatology 2012-01-15

Severe systemic inflammation associated with some stages of COVID-19 and in fatal cases led therapeutic agents developed or used frequently Rheumatology being at the vanguard experimental therapeutics strategies. The aim this project was to elaborate EULAR Points consider (PtCs) on pathophysiology immunomodulatory therapies.PtCs were accordance standard operating procedures for endorsed recommendations, by an international multidisciplinary Task Force, including rheumatologists,...

10.1136/annrheumdis-2020-219724 article EN cc-by-nc Annals of the Rheumatic Diseases 2021-02-05

The aim of the study was to evaluate pattern lymphoid organization in synovial tissue patients affected with juvenile idiopathic arthritis (JIA).A total 40 JIA who underwent synoviectomy or biopsies were enrolled. mean age at surgery 15.1 yrs (range 6-30 yrs) and disease duration 6.7 3 months 22.2 yrs). Tissue specimens grouped according following criteria: (i) diffuse perivascular infiltrate without organization, (ii) T cell-B cell aggregates germinal centre reaction.Synovial tissues from...

10.1093/rheumatology/kel225 article EN Lara D. Veeken 2006-07-28

<h3>Objective.</h3> To compare the power Doppler ultrasonography (PDUS) pictures of peripheral entheses in patients with psoriatic arthritis (PsA) and fibromyalgia (FM). <h3>Methods.</h3> Thirty PsA 30 FM participating a study aimed at identifying clinical features that distinguish 2 conditions underwent PDUS assessment 14 major entheses. All detected entheseal changes were recorded scored, data statistically analyzed by means univariate analysis receiver-operating characteristic curves....

10.3899/jrheum.120238 article EN Journal of Rheumatology Supplement 2012-07-01

The novel SARS-CoV-2 vaccines partially exploit intrinsic DNA or RNA adjuvanticity, with dysregulation in the metabolism of both these nucleic acids independently linked to triggering experimental autoimmune diseases, including lupus and myositis.Herein, we present 15 new onset myositis temporally associated DNA-based that occurred between February 2021 April 2022. Musculoskeletal, pulmonary, cutaneous cardiac manifestations, laboratory imaging data were collected.In total, cases (11...

10.3390/vaccines10081184 article EN cc-by Vaccines 2022-07-26

To report adverse events registered in our population affected by JIA and treated with anti-TNFalpha blockers.Ninety-five patients were enrolled to be Etanercept, median age 14 years (range 4-34); duration of therapy 12 months 1-40). 19 also MTX (median dose 12.5 mg/week). Fifty-six Infliximab associated 8.8 mg/week), 23.2 7.8-34.9); 20.1 1.4-60.4). All divided definitely, probably possibly related the biologic agent.Side effects definitely reactions infusions Anti-dsDNA positivity. Side...

10.4081/reumatismo.2006.31 article EN cc-by-nc Reumatismo 2011-09-12
Coming Soon ...